BG106022A - Нови полиморфни форми на противодиабетично средство: метод за тяхното получаване и фармацевтични състави, които ги съдържат - Google Patents

Нови полиморфни форми на противодиабетично средство: метод за тяхното получаване и фармацевтични състави, които ги съдържат Download PDF

Info

Publication number: BG106022A
Authority: BG; Bulgaria
Prior art keywords: ethoxy; phenyl; phenoxazin; ethoxypropanoic acid; arginine salt
Prior art date: 1999-04-16

Application number

BG106022A

Other languages

Bulgarian (bg)

English (en)

Inventor

Om GADDAM

Rajender POTLAPALLY

Raju Sirisilla

Vyas Krishnamurthi

Sreenivasa DHARMARAJA

Ramabhadra MAMILLAPALLI

Original Assignee

Dr. Reddy's Laboratories Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-16

Filing date

2001-10-16

Publication date

2002-04-30

1999-04-16 Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en

2001-10-16 Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited

2002-04-30 Publication of BG106022A publication Critical patent/BG106022A/bg

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
238000000034 method Methods 0.000 title claims description 80
238000002360 preparation method Methods 0.000 title claims description 36
230000008569 process Effects 0.000 title claims description 19
239000003472 antidiabetic agent Substances 0.000 title abstract description 4
229940125708 antidiabetic agent Drugs 0.000 title description 2
WMUIIGVAWPWQAW-UHFFFAOYSA-N 2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-UHFFFAOYSA-N 0.000 claims abstract description 76
239000000203 mixture Substances 0.000 claims abstract description 51
239000003937 drug carrier Substances 0.000 claims abstract description 8
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical class OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 96
238000003756 stirring Methods 0.000 claims description 57
239000002244 precipitate Substances 0.000 claims description 54
WMUIIGVAWPWQAW-DEOSSOPVSA-N (2s)-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-DEOSSOPVSA-N 0.000 claims description 53
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
239000000243 solution Substances 0.000 claims description 46
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 45
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 39
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 39
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
229930064664 L-arginine Natural products 0.000 claims description 36
235000014852 L-arginine Nutrition 0.000 claims description 36
238000011282 treatment Methods 0.000 claims description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
125000004557 phenoxazin-10-yl group Chemical group C1=CC=CC=2OC3=CC=CC=C3N(C12)* 0.000 claims description 34
239000011541 reaction mixture Substances 0.000 claims description 33
238000001914 filtration Methods 0.000 claims description 30
-1 (2S) L-arginine salt 3- [4- [2- (Phenoxazin-10-yl) ethoxy] phenyl] -2-ethoxypropanoic acid Chemical compound 0.000 claims description 29
238000002441 X-ray diffraction Methods 0.000 claims description 28
206010022489 Insulin Resistance Diseases 0.000 claims description 27
125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 27
201000010099 disease Diseases 0.000 claims description 27
208000008589 Obesity Diseases 0.000 claims description 26
238000010521 absorption reaction Methods 0.000 claims description 26
208000035475 disorder Diseases 0.000 claims description 26
235000020824 obesity Nutrition 0.000 claims description 26
239000000843 powder Substances 0.000 claims description 26
208000029078 coronary artery disease Diseases 0.000 claims description 25
238000001035 drying Methods 0.000 claims description 25
108010007622 LDL Lipoproteins Proteins 0.000 claims description 23
102000007330 LDL Lipoproteins Human genes 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 23
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 22
230000002194 synthesizing effect Effects 0.000 claims description 22
LCBJEJLDEGRRPF-OMTJCYKGSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 LCBJEJLDEGRRPF-OMTJCYKGSA-N 0.000 claims description 21
208000002705 Glucose Intolerance Diseases 0.000 claims description 20
208000031226 Hyperlipidaemia Diseases 0.000 claims description 20
208000024172 Cardiovascular disease Diseases 0.000 claims description 19
201000009104 prediabetes syndrome Diseases 0.000 claims description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
208000001132 Osteoporosis Diseases 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 17
206010020772 Hypertension Diseases 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 16
239000003960 organic solvent Substances 0.000 claims description 16
235000012000 cholesterol Nutrition 0.000 claims description 15
201000010065 polycystic ovary syndrome Diseases 0.000 claims description 15
201000001320 Atherosclerosis Diseases 0.000 claims description 14
208000035150 Hypercholesterolemia Diseases 0.000 claims description 14
102000016267 Leptin Human genes 0.000 claims description 14
108010092277 Leptin Proteins 0.000 claims description 14
206010036049 Polycystic ovaries Diseases 0.000 claims description 14
108010062497 VLDL Lipoproteins Proteins 0.000 claims description 14
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 14
229940039781 leptin Drugs 0.000 claims description 14
208000011580 syndromic disease Diseases 0.000 claims description 14
239000003826 tablet Substances 0.000 claims description 14
238000010992 reflux Methods 0.000 claims description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
102000004316 Oxidoreductases Human genes 0.000 claims description 11
108090000854 Oxidoreductases Proteins 0.000 claims description 11
238000010438 heat treatment Methods 0.000 claims description 11
239000003112 inhibitor Substances 0.000 claims description 11
229960003512 nicotinic acid Drugs 0.000 claims description 11
235000001968 nicotinic acid Nutrition 0.000 claims description 11
239000011664 nicotinic acid Substances 0.000 claims description 11
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 11
229960003912 probucol Drugs 0.000 claims description 11
206010003210 Arteriosclerosis Diseases 0.000 claims description 10
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 10
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 10
208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
206010012601 diabetes mellitus Diseases 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
208000017169 kidney disease Diseases 0.000 claims description 10
150000003626 triacylglycerols Chemical class 0.000 claims description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
229920001268 Cholestyramine Polymers 0.000 claims description 9
206010012289 Dementia Diseases 0.000 claims description 9
208000032928 Dyslipidaemia Diseases 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
206010018364 Glomerulonephritis Diseases 0.000 claims description 9
208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
206010068871 Myotonic dystrophy Diseases 0.000 claims description 9
206010029164 Nephrotic syndrome Diseases 0.000 claims description 9
206010033645 Pancreatitis Diseases 0.000 claims description 9
201000004681 Psoriasis Diseases 0.000 claims description 9
239000003288 aldose reductase inhibitor Substances 0.000 claims description 9
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims description 9
230000003920 cognitive function Effects 0.000 claims description 9
210000002889 endothelial cell Anatomy 0.000 claims description 9
206010061989 glomerulosclerosis Diseases 0.000 claims description 9
201000009925 nephrosclerosis Diseases 0.000 claims description 9
239000003614 peroxisome proliferator Substances 0.000 claims description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
108010016731 PPAR gamma Proteins 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
238000001816 cooling Methods 0.000 claims description 8
235000021588 free fatty acids Nutrition 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
102000023984 PPAR alpha Human genes 0.000 claims description 7
230000008993 bowel inflammation Effects 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
239000008103 glucose Substances 0.000 claims description 7
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 7
239000012453 solvate Substances 0.000 claims description 7
238000001291 vacuum drying Methods 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
230000008289 pathophysiological mechanism Effects 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 6
102000004877 Insulin Human genes 0.000 claims description 5
108090001061 Insulin Proteins 0.000 claims description 5
206010048214 Xanthoma Diseases 0.000 claims description 5
206010048215 Xanthomatosis Diseases 0.000 claims description 5
239000000556 agonist Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
229940125396 insulin Drugs 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
102000004895 Lipoproteins Human genes 0.000 claims description 4
108090001030 Lipoproteins Proteins 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000006188 syrup Substances 0.000 claims description 4
235000020357 syrup Nutrition 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 3
238000004108 freeze drying Methods 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
FKRZCZBWVCZZLM-IBGZPJMESA-N C1=CC=CC=2OC3=CC=CC=C3N(C12)CCOC1=CC=C(C=C1)C[C@H](C)OCC Chemical compound C1=CC=CC=2OC3=CC=CC=C3N(C12)CCOC1=CC=C(C=C1)C[C@H](C)OCC FKRZCZBWVCZZLM-IBGZPJMESA-N 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
238000005406 washing Methods 0.000 claims description 2
208000017442 Retinal disease Diseases 0.000 claims 16
206010038923 Retinopathy Diseases 0.000 claims 16
229920002911 Colestipol Polymers 0.000 claims 9
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 9
229960002604 colestipol Drugs 0.000 claims 9
201000001421 hyperglycemia Diseases 0.000 claims 9
229940125753 fibrate Drugs 0.000 claims 8
230000002265 prevention Effects 0.000 claims 8
208000002249 Diabetes Complications Diseases 0.000 claims 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 4
230000010030 glucose lowering effect Effects 0.000 claims 3
230000001631 hypertensive effect Effects 0.000 claims 3
230000002611 ovarian Effects 0.000 claims 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
201000005577 familial hyperlipidemia Diseases 0.000 claims 2
230000007310 pathophysiology Effects 0.000 claims 2
229940126033 PPAR agonist Drugs 0.000 claims 1
102000000536 PPAR gamma Human genes 0.000 claims 1
239000000835 fiber Substances 0.000 claims 1
229940127208 glucose-lowering drug Drugs 0.000 claims 1
230000001991 pathophysiological effect Effects 0.000 claims 1
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
238000006467 substitution reaction Methods 0.000 claims 1
230000003178 anti-diabetic effect Effects 0.000 abstract description 3
239000003524 antilipemic agent Substances 0.000 abstract description 2
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
238000000113 differential scanning calorimetry Methods 0.000 description 27
238000000634 powder X-ray diffraction Methods 0.000 description 13
238000000862 absorption spectrum Methods 0.000 description 12
238000001757 thermogravimetry curve Methods 0.000 description 12
210000004027 cell Anatomy 0.000 description 8
108010010234 HDL Lipoproteins Proteins 0.000 description 7
102000015779 HDL Lipoproteins Human genes 0.000 description 7
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
150000001483 arginine derivatives Chemical class 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
108010023302 HDL Cholesterol Proteins 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000004475 Arginine Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
238000004566 IR spectroscopy Methods 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
108020005497 Nuclear hormone receptor Proteins 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009697 arginine Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000005265 energy consumption Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000000055 hyoplipidemic effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
102000006255 nuclear receptors Human genes 0.000 description 2
108020004017 nuclear receptors Proteins 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
JHBWYQRKOUBPCA-UHFFFAOYSA-N 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)NC1=CC=CC=C1 JHBWYQRKOUBPCA-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
REJLEEWOIVMIPR-UHFFFAOYSA-N 2-ethoxy-2-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound CCOC(C)(C(O)=O)c1ccc(OCCN2c3ccccc3Oc3ccccc23)cc1 REJLEEWOIVMIPR-UHFFFAOYSA-N 0.000 description 1
XBHQOMRKOUANQQ-UHFFFAOYSA-N 2-ethoxypropanoic acid Chemical compound CCOC(C)C(O)=O XBHQOMRKOUANQQ-UHFFFAOYSA-N 0.000 description 1
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000000057 Coronary Stenosis Diseases 0.000 description 1
206010011089 Coronary artery stenosis Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
230000019439 energy homeostasis Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
231100000502 fertility decrease Toxicity 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229950008364 frentizole Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
230000004140 ketosis Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
206010065579 multifocal motor neuropathy Diseases 0.000 description 1
230000003387 muscular Effects 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
230000003880 negative regulation of appetite Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000016438 regulation of fat cell differentiation Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960003660 sertraline hydrochloride Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
229960001544 sulfathiazole Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

BG106022A 1999-04-16 2001-10-16 Нови полиморфни форми на противодиабетично средство: метод за тяхното получаване и фармацевтични състави, които ги съдържат BG106022A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB1999/000681 WO2000063191A1 (en)	1999-04-16	1999-04-16	Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999		1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en)	1999-04-16	2000-04-17	Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number	Publication Date
BG106022A true BG106022A (bg)	2002-04-30

Family

ID=26318745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106022A BG106022A (bg)	1999-04-16	2001-10-16	Нови полиморфни форми на противодиабетично средство: метод за тяхното получаване и фармацевтични състави, които ги съдържат

Country Status (17)

Country	Link
EP (1)	EP1171430A1 (pt)
CN (1)	CN1351597A (pt)
AU (1)	AU3831300A (pt)
BG (1)	BG106022A (pt)
BR (1)	BR0010683A (pt)
CA (1)	CA2370401A1 (pt)
CZ (1)	CZ20013711A3 (pt)
EE (1)	EE200100529A (pt)
HR (1)	HRP20010748A2 (pt)
HU (1)	HUP0200758A3 (pt)
IL (1)	IL145958A0 (pt)
MX (1)	MXPA01010472A (pt)
NO (1)	NO20015016L (pt)
PL (1)	PL351492A1 (pt)
RU (1)	RU2001130883A (pt)
TR (1)	TR200103851T2 (pt)
WO (1)	WO2000063192A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60114996T2 (de)	2000-03-08	2006-08-10	Novo Nordisk A/S	Senkung des serum cholesterols
US6897199B2 (en) *	2001-02-05	2005-05-24	Dr. Reddy's Laboratories Ltd.	Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP2243776A1 (en)	2001-10-12	2010-10-27	High Point Pharmaceuticals, LLC	Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003055482A1 (en)	2001-12-21	2003-07-10	Novo Nordisk A/S	Amide derivatives as gk activators
SI1505066T1 (sl) *	2002-04-19	2007-04-30	Faes Farma Sa	Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
AU2003243921B2 (en)	2002-06-27	2009-05-07	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
DE602004022153D1 (de)	2003-05-14	2009-09-03	High Point Pharmaceuticals Llc	Verbindungen zur behandlung von obesitas
MXPA06003474A (es)	2003-09-30	2006-06-05	Novo Nordisk As	Agonistas de receptores de melanocortina.
WO2005056036A2 (en)	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
PT1723128E (pt)	2004-01-06	2013-02-27	Novo Nordisk As	Heteroaril-ureias e o seu uso como activadores da glicoquinase
JP2007536344A (ja)	2004-05-04	2007-12-13	ノボ　ノルディスク　アクティーゼルスカブ	新規のインドール誘導体
EP1758575A1 (en)	2004-06-11	2007-03-07	Novo Nordisk A/S	Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (zh)	2004-11-22	2011-01-19	诺和诺德公司	可溶、稳定的含胰岛素制剂
US8148412B2 (en)	2004-12-03	2012-04-03	Novo Nordisk A/S	Heteroaromatic glucokinase activators
EP2386554A1 (en)	2005-07-04	2011-11-16	High Point Pharmaceuticals, LLC	Compounds active at the histamine H3 receptor
BRPI0612996A2 (pt)	2005-07-14	2010-12-14	Novo Nordisk As	ativadores de urÉia glucocinase
US8106090B2 (en)	2005-07-20	2012-01-31	Eli Lilly And Company	1-amino linked compounds
DK1951658T3 (da)	2005-11-17	2012-10-15	Lilly Co Eli	Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US8394842B2 (en)	2006-03-28	2013-03-12	High Point Pharmaceuticals, Llc	Benzothiazoles having histamine H3 receptor activity
EP2079732B9 (en)	2006-05-29	2012-03-21	High Point Pharmaceuticals, LLC	3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
US8022066B2 (en)	2006-11-15	2011-09-20	High Point Pharmaceuticals, Llc	2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
EP2097388B1 (en)	2006-11-15	2011-09-07	High Point Pharmaceuticals, LLC	Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
AU2008204530B2 (en)	2007-01-11	2013-08-01	Vtv Therapeutics Llc	Urea glucokinase activators
JP2010013472A (ja) *	2009-09-09	2010-01-21	Faes Farma Sa	４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt)	2010-02-26	2015-09-08	Basf Plant Science Co Gmbh	método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011104378A1 (en)	2010-02-26	2011-09-01	Novo Nordisk A/S	Peptides for treatment of obesity
EP2552950A1 (en)	2010-03-26	2013-02-06	Novo Nordisk A/S	Novel glucagon analogues
EP2670368A4 (en)	2011-02-03	2015-04-15	Pharmedica Ltd	NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
RU2013145013A (ru)	2011-03-28	2015-05-10	Ново Нордиск А/С	Новые аналоги глюкагона
MY167234A (en)	2011-09-23	2018-08-14	Novo Nordisk As	Novel glucagon analogues
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
MY174727A (en)	2013-04-18	2020-05-11	Novo Nordisk As	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
JP2020514365A (ja)	2017-03-15	2020-05-21	ノヴォノルディスクアー／エス	メラノコルチン４受容体に結合可能な二環式化合物
WO2019219714A1 (en)	2018-05-15	2019-11-21	Novo Nordisk A/S	Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en)	2018-09-14	2020-03-19	Novo Nordisk A/S	Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5089514A (en) *	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) *	1992-08-13	1993-09-28	Pfizer Inc.	Sertraline polymorph
IN182496B (pt) *	1996-02-20	1999-04-17	Reddy Research Foundation
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
FR2746099B1 (fr) *	1996-03-13	1998-04-30		Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
CN1196730A (zh) *	1996-06-19	1998-10-21	雷迪博士研究基金会	具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
WO1999019313A1 (en) *	1997-10-27	1999-04-22	Dr. Reddy's Research Foundation	Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU1887999A (en) *	1998-01-29	1999-08-16	Dr. Reddy's Research Foundation	Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) *	1998-05-27	2002-03-12	ドクター・レディーズ・リサーチ・ファウンデーション	二環系化合物、その製造方法およびそれらを含有する薬学的組成物

2000
- 2000-04-17 TR TR2001/03851T patent/TR200103851T2/xx unknown
- 2000-04-17 CN CN00807705A patent/CN1351597A/zh active Pending
- 2000-04-17 HR HR20010748A patent/HRP20010748A2/hr not_active Application Discontinuation
- 2000-04-17 EP EP00917222A patent/EP1171430A1/en not_active Withdrawn
- 2000-04-17 CA CA002370401A patent/CA2370401A1/en not_active Abandoned
- 2000-04-17 HU HU0200758A patent/HUP0200758A3/hu unknown
- 2000-04-17 RU RU2001130883/04A patent/RU2001130883A/ru unknown
- 2000-04-17 WO PCT/IB2000/000470 patent/WO2000063192A1/en not_active Ceased
- 2000-04-17 MX MXPA01010472A patent/MXPA01010472A/es unknown
- 2000-04-17 CZ CZ20013711A patent/CZ20013711A3/cs unknown
- 2000-04-17 IL IL14595800A patent/IL145958A0/xx unknown
- 2000-04-17 PL PL00351492A patent/PL351492A1/xx not_active Application Discontinuation
- 2000-04-17 BR BR0010683-6A patent/BR0010683A/pt not_active IP Right Cessation
- 2000-04-17 EE EEP200100529A patent/EE200100529A/xx unknown
- 2000-04-17 AU AU38313/00A patent/AU3831300A/en not_active Abandoned
2001
- 2001-10-15 NO NO20015016A patent/NO20015016L/no not_active Application Discontinuation
- 2001-10-16 BG BG106022A patent/BG106022A/bg unknown

Also Published As

Publication number	Publication date
CA2370401A1 (en)	2000-10-26
RU2001130883A (ru)	2004-03-20
HRP20010748A2 (en)	2003-02-28
TR200103851T2 (tr)	2002-04-22
IL145958A0 (en)	2002-07-25
BR0010683A (pt)	2003-07-01
AU3831300A (en)	2000-11-02
NO20015016D0 (no)	2001-10-15
EE200100529A (et)	2002-12-16
CZ20013711A3 (cs)	2002-07-17
CN1351597A (zh)	2002-05-29
NO20015016L (no)	2001-12-11
HUP0200758A3 (en)	2003-07-28
WO2000063192A1 (en)	2000-10-26
HUP0200758A2 (hu)	2002-07-29
MXPA01010472A (es)	2002-05-06
PL351492A1 (en)	2003-04-22
EP1171430A1 (en)	2002-01-16

Publication	Publication Date	Title
MXPA01010472A (es)	2002-05-06	Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
JP2003508348A (ja)	2003-03-04	新規多型形態の抗糖尿病薬剤：それらの製造方法およびそれらを含有する医薬組成物
WO2000063193A1 (en)	2000-10-26	Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
CA2426117A1 (en)	2002-04-04	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
ZA200106994B (en)	2003-11-25	Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them.
US6528507B1 (en)	2003-03-04	Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2002028857A1 (en)	2002-04-11	Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
EP1363913A2 (en)	2003-11-26	Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
US20040068116A1 (en)	2004-04-08	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
JP2010248246A (ja)	2010-11-04	５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
US20020169175A1 (en)	2002-11-14	Pharmaceutically acceptable salts of heterocyclic compounds
WO2003066612A1 (en)	2003-08-14	Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them
RU2286345C2 (ru)	2006-10-27	Полиморфные кристаллические формы 5-[4-2-[n-метил-n-(2-пиридил)амино]этокси]бензил]тиазолидин-2,4-дион малеата
SK1452003A3 (en)	2004-05-04	Tartrate salts of thiazolidinedione derivative
AU2001291232A1 (en)	2002-06-20	Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
HK1213549B (en)	2018-06-15	Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
HK1213549A1 (en)	2016-07-08	Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof